Telemedicine Evaluation for Stem Cell Transplant Patients

Not Applicable

Completed

• Conditions: Stem Cell Transplant Patients
• Interventions: Behavioral: virtual medical visit

• Registration Number: NCT01324427
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

Telemedicine is a new area of health care where medical information is transferred through audiovisual media, such as a computer or a video camera, for the purpose of remote doctor's visits or examinations. This new area of health care is important to test because it can potentially provide real-time interactions between the patient and their health care team, including phone conversations, online communication, and/or home visits. Many activities such as a history review or physical examination can be conducted virtually as compared to the traditional face-to face visits.

The purpose of this study is to determine patient and health care team acceptance of a "virtual medical visit" as a substitute for a "face to face" visit for patients either preparing to receive a stem cell transplant or previously received a stem cell transplant.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-03
• Study First Submitted: 2011-03-24
• Study First Submitted QC: 2011-03-25
• Study First Posted: 2011-03-29
• Status Verified: 2020-08
• Primary Completion: 2020-08
• Study Completion: 2020-08
• Last Update Submitted: 2020-08-12
• Last Update Posted: 2020-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• Patients who underwent or are planning to undergo a hematopoietic progenitor cell transplantation for any disease.
• Participants must be able to read and understand English*
• Age over 18 years of age since this pilot trial is only being performed in the Adult BMT Service Non-English speaking patients have been excluded in this pilot study because we do not have the support for translation services at this time. Additionally, the telemedicine instruments being used are not yet validated across all languages.

Potential patients will be identified according to their medical condition, type and complexity of stem cell transplant procedure performed, and distance from MSKCC.

The patients should:

1. minimal comorbidities,
2. be less than 75 years of age. These characteristics have been associated with good understanding and acceptance of telemedicine in other pilot trials. These characteristics will be assessed by the clinician.

Please note: Patients on other therapeutic protocols will be eligible for this protocol as well.

Read More

Exclusion Criteria

• Medically unstable patient as deemed by the treating team.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
virtual medical visit	virtual medical visit	This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a "virtual medical visit" by patients and health care personnel. During this pilot trial we expect to perform 84 "virtual medical visits" using telemedicine.

Primary Outcome Measures

Name	Time	Method
Determine patient & physician acceptance of a "virtual medical visit" as a substitute for a "face to face" in pts in different settings. This is assessed by analyzing answers to questions 7 & 8 of the Patient Satisfaction Survey. [Question #7: I would	2 years	Question #8: Overall, I was very satisfied with today's telemedicine session.\]Physician acceptance will be analyzed looking at the answers to question 19 of the Physician/Nurse survey in which the physician or nurse investigator relates the quality of the telemedicine visit. \[Question #19: How would you rate the quality of the Telehealth visit to assess the patient compared to an in-person office visit?\]

Secondary Outcome Measures

Name	Time	Method
Confirm that current telemedicine technology a comprehensive stem cell transplant clinical evaluation can be performed.	2 years	Questions 1-12 of the healthcare provider survey will assess the quality of the information \&assessment collected through the "virtual medical visit".
Evaluate the feasibility of telemedicine facilitated "handoffs" between the inpatient and the outpatient service at the time of discharge from the inpatient service and at the time of discharge from the transplant center are feasible and useful.	2 years	The instrument used to analyze the feasibility and utility of the handoff instrument is Provider Satisfaction Survey with Handoff Instrument Survey for Feedback on Handoff Instrument. We will collate these responses to determine whether the handoff instrument was found to be useful and what elements should be modified, removed or added.
Describe the logistic characteristics of a "virtual medical visit" performed using telemedicine such as visit times, connection quality, and quality of the clinical information obtained.	2 years	The time from the first attempt to connect until the time to disconnect will be captured for all encounters as well as the time from the beginning to end of the "virtual medical visit". We expect that the "virtual medical visit" should take on average 20 minutes from attempt to connect to disconnect.

Trial Locations

Locations (4)

Memorial Sloan-Kettering Cancer Center @ Suffolk; 🇺🇸 Commack, New York, United States

Memoral Sloan Kettering Cancer Center; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center; 🇺🇸 Sleepy Hollow, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States